SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Vincenzo et.al found that Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced hepatic and cardiac inflammation in doxorubicin-treated mice which could be effective to reduce the presence and progression of both NAFLD and cardiovascular diseases [33].